NSAIDs for the Chemoprevention of Oral Cancer: Promise or Pessimism?

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1561-1564

  Goodin, Susan ^a   Shiff, Steven J ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KETOROLAC; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BCL 2; PROTEIN P53; RETINOID; TRANSFORMING GROWTH FACTOR ALPHA;

CANCER PREVENTION; CATALYSIS; CELL PROLIFERATION; COLON CANCER; DRUG EFFICACY; GENE OVEREXPRESSION; HUMAN; INHIBITION KINETICS; LEUKOPLAKIA; MOUTH CANCER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TONGUE CANCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS, PHASE II; CYCLOOXYGENASE INHIBITORS; HUMANS; MOUTH MUCOSA; MOUTH NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 1842481940     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0003-4     Document Type: Review

References (43)

1. Pindborg, J. J., Reichart, P. A., Smith, C. J., and van der Waal, I. (eds.), Histological Typing of Cancer and Precanceer of the Oral Mucosa, Ed. 2, pp. 21-26. Berlin, Germany: Springer-Verlag, 1997.
2. Lodi, G., Sardella, A., Bez, C., Demarosi, F., and Carrassi A. Systemic review of randomized trials for the treatment of oral leukoplakia. J. Dent. Educ., 66: 896-902, 2002.
3. Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med., 315: 1501-1505, 1986.
4. Slaugheter, D. P., Southwick, H. W., and Smejkal W. Field cancerization in oral stratified squamous epithelium. Cancer (Phila.), 6: 963-968, 1953.
5. Sudbo, J., Kildal, W., Risberg, B., Koppang, H. S., Danielsen, J. E., and Reith, A. DNA content as a prognostic marker in patients with oral leukoplakia. N. Engl. J. Med., 344: 1270-1278, 2001.
6. Reith, A., and Sudbo, J. Impact of genomic instability in risk assessment and chemoprevention of oral premalignancies. Int. J. Cancer, 101: 205-209, 2002.
7. Mao, L., Lee, J. S., Fan, Y. H., Ro, J. Y., Batsakis, J. G., Lippmann, S., et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat. Med., 2: 682-685, 1996.
8. Emilion, G., Langdon, J. D., Speight, P., and Partridge, M. Frequent gene deletions in potentially malignant oral lesions. Br. J. Cancer, 73: 809-813, 1996.
9. Nees, M., Homann, N., Discher, H., Andl, T., Enders, C., Herold-Mende, C., et al. Expression of mutated p53 occurs in tumor-distant epithelial head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res., 53: 4189-4196, 1993.
10. Lee, J. J., Hong, W. K., Hittelman, W. N., Mao, L., Lotan, R., Shin, D. M., et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin. Cancer Res., 6: 1702-1710, 2000.
11. Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348: 891-899, 2003.
12. Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med., 348: 883-890, 2003.
13. Chan, G., Boyle, J. O., Yang, E. K., Zhang, F., Sacks, P. G., Shah, J. P., et al. Cyclooxygenase-2 expression up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59: 9991-9994, 1999.
14. Marnett, L. J. Generation of mutagens during arachidonic acid metabolism. Cancer Metastasis Rev., 13: 303-308, 1994.
15. Tsujii, M., and DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 705-716, 1995.
16. Leahy, K. M., Koki, A. T., and Masferrer, J. L. Role of cyclooxygenases in angiogenesis. Curr. Med. Chem., 7: 1163-1170, 2000.
17. Renkonen, J., Wolff, H., and Paavonen, T. Expression of cyclooxygenase-2 in human tongue carcinoma and precursor lesions. Virchows Archiv., 440: 594-597, 2002.
18. Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D., and Heath, C. W., Jr. Aspirin use and risk of fatal cancer. Cancer Res., 53: 1322-1327, 1993.
19. Tanaka, T., Nishikawa, A., Mori, Y., Morishita, Y., and Mori, H. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett., 48: 177-182, 1989.
20. Perkins, T. M., and Shklar, G. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral Surg. Oral Med. Oral Pathol., 53: 170-178, 1982.
21. Wang, Z., Fuentes, C. F., and Shapshay, S. M. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cells. Laryngoscope, 112: 839-843, 2002.
22. Shiotani, H., Denda, A., Yamamoto, K., Kitayama, W., Endoh, T., Sasaki, Y. K., et al. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline 1-oxide induced rate tongue carcinoma and chemopreventive efficacy of a specific inhibitor of nimesulide. Cancer Res., 61: 1451-1456, 2001.
23. Tsujii, M., and DuBois, R. N. Alteration in cellular adhesion and apoptosis in epithelial cells over expressing prostaglandin endoperoxide synthase-2. Cell, 83: 493-501, 1995.
24. Loro, L. L., Johannessen, A. C., and Bintermyr, O. K. Decreased expression of bcl-2 in moderate and severe oral epithelial dysplasias. Oral Oncol., 38: 691-698, 2002.
25. Subbaramaiah, K., Altorki, N., Chung, W. J., Mestre, J. R., and Sampat, A. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem., 274: 10911-10915, 1999.
26. Hong, W., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795-801, 1990.
27. Shiff, S. J., Qiao, L., Tsai, L. L., and Rigas, B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J. Clin. Investig., 96: 491-503, 1995.
28. Shiff, S. J., Shivaprasad, P., and Santini, D. L. Cyclooxygenase inhibitors: drugs for cancer prevention. Curr. Opin. Pharmacol., 3: 352-361, 2003.
29. Jaeckel, E. C., Raja, S., Tan, J., Das, S. K., Dey, S. K., Girod, D. A., et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferators-activated receptor delta with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg., 127: 1253-1259, 2001.
30. Gallo, O., Franchi, A., Magnelli, L., Sardi, L., Boddi, V., Chiarugi, V., et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer: implications for angiogensis and metastasis. Neoplasia, 3: 53-61, 2001.
31. Chen, Y. J., Jin, Y. T., Shieh, D. B., Tsai, S. T., and Wu, L. W. Molecular characterization of angiogenic properties of human oral squamous cell carcinoma cells. Oral Oncol., 38: 699-702, 2002.
32. Tsujii, M., Kawano, S., Tsujii, S., Sawaoka, H., Hori, M., and Dubois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cells, 93: 705-715, 1998.
33. Tsujii, M., Kawano, S., and DuBois, R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA, 94: 3336-3340, 1997.
34. Tomozawa, S., Nagawa, H., Tsuno, N., Hatano, K., Osada, L., Kitayama, J., et al. Inhibition of hematogenous metastasis of colon cancer in mice by a selective Cox-2 inhibitor, JTE522. Br. J. Cancer, 81: 1274-1279, 1999.
35. Shirasun, K., Hayashido, Y., Sugiyama, M., Yoshioka, H., and Matsuya, T. Immunohistochemical localization of epidermal growth factor (EGF) and EGF receptor in human oral mucosa and its malignancy. Virchows Arch. Pathol. Anat., 41: 349-353, 1991.
36. Mestre, J. R., Subbaramaiah, K., Sacks, P. G., Stimson, P., Schantz, S. P., Tanabe, T., et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res., 57: 2890-2895, 1997.
37. Soh, J. W., and Weinstein, I. B. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog. Exp. Tumor Res., 37: 261-285, 2003.
38. Beenken, S. W., Hockett, R., Grizzle, W., Weiss, H. L., Pickens, A., Perloff, M., et al. Transforming growth factor-α: a surrogate endpoint biomarker? J. Am. Coll. Surg., 195: 149-158, 2002.
39. Wang, Z., Polavaram, R., and Shapshay, S. M. Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. Cancer Lett., 198: 53-58, 2003.
40. Mulshine, J. L., Atkinson, J. C., Greer, R. O., Papadimitrakopoulou, V. A., Van Waes, C., Rudy, S., et al. Randomized, double-blind, placebo-controlled, Phase IIB trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin. Cancer Res., 10: 1565-1573, 2004.
41. Hong, S. H., Ondtey, F. G., Avis, I. M., Chen, Z., Loukinova, E., Cavanaugh, P. F., et al. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation? FASEB J., 14: 1449-1507, 2000.
42. Kelly, D. J., Mestre, J. R., Subramaniak, K., Sacks, P. G., Schantz, S. P., Tanabe, T., et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis (Lond.), 18: 795-799, 1997.
43. Eling, T. E., Thompson, D. C., Foureman, G. L., Curtis, J. F., and Hughes, M. F. Prostaglandin H synthase and xenobiotic oxidation. Annu. Rev. Pharmacol. Toxicol., 30: 1-45, 1990.